VOLUME 6 (2015)
Table of Contents
Editorial
|
| Base excision DNA repair and cancer |
|
https://doi.org/10.18632/oncotarget.2705
|
| 584-585 |
|
| TORC2 inhibition may boost DNAdamaging chemotherapy |
|
https://doi.org/10.18632/oncotarget.3034
|
| 586-587 |
|
| Predicting response to HER2 kinase inhibition |
|
https://doi.org/10.18632/oncotarget.3036
|
| 588-589 |
Reviews
|
| Androgen receptors beyond prostate cancer: an old marker as a new target |
|
https://doi.org/10.18632/oncotarget.2831
|
| 592-603 |
Priority Research Papers
|
| Estrogen receptor alpha drives proliferation in PTENdeficient prostate carcinoma by stimulating survival signaling MYC expression and altering glucose sensitivity |
|
https://doi.org/10.18632/oncotarget.2820
|
| 604-616 |
|
| Screening analysis of ubiquitin ligases reveals G2E3 as a potential target for chemosensitizing cancer cells |
|
https://doi.org/10.18632/oncotarget.2710
|
| 617-632 |
Research Papers: Gerotarget (Focus on Aging)
|
| Impact of age on the survival of patients with liver cancer: an analysis of 27255 patients in the SEER database |
|
https://doi.org/10.18632/oncotarget.2719
|
| 633-641 |
|
| Synthetic Aβ peptides acquire prionlike properties in the brain |
|
https://doi.org/10.18632/oncotarget.2819
|
| 642-650 |
Research Papers
|
| Targeting the facilitative glucose transporter GLUT1 inhibits the selfrenewal and tumorinitiating capacity of cancer stem cells |
|
https://doi.org/10.18632/oncotarget.2892
|
| 651-661 |
|
| Inhibition of the Warburg effect with a natural compound reveals a novel measurement for determining the metastatic potential of breast cancers |
|
https://doi.org/10.18632/oncotarget.2689
|
| 662-678 |
|
| IL1RT1 signaling antagonizes IL11 induced STAT3 dependent cardiac and antral stomach tumor development through myeloid cell enrichment |
|
https://doi.org/10.18632/oncotarget.2707
|
| 679-695 |
|
| Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS |
|
https://doi.org/10.18632/oncotarget.2673
|
| 696-714 |
|
| Cancer exosomes trigger mesenchymal stem cell differentiation into proangiogenic and proinvasive myofibroblasts |
|
https://doi.org/10.18632/oncotarget.2711
|
| 715-731 |
|
| SWI/SNF complexes are required for full activation of the DNAdamage response |
|
https://doi.org/10.18632/oncotarget.2715
|
| 732-745 |
|
| A subgroup of pancreatic adenocarcinoma is sensitive to the 5azadC DNA methyltransferase inhibitor |
|
https://doi.org/10.18632/oncotarget.2685
|
| 746-754 |
|
| The genomic landscape of fibrolamellar hepatocellular carcinoma: whole genome sequencing of ten patients |
|
https://doi.org/10.18632/oncotarget.2712
|
| 755-770 |
|
| SKP2 inactivation suppresses prostate tumorigenesis by mediating JARID1B ubiquitination |
|
https://doi.org/10.18632/oncotarget.2718
|
| 771-788 |
|
| P62 regulates resveratrolmediated Fas/Cav1 complex formation and transition from autophagy to apoptosis |
|
https://doi.org/10.18632/oncotarget.2733
|
| 789-801 |
|
| The PI3K inhibitor GDC0941 displays promising in vitro and in vivo efficacy for targeted medulloblastoma therapy |
|
https://doi.org/10.18632/oncotarget.2742
|
| 802-813 |
|
| Shorthairpin RNA library: identification of therapeutic partners for gefitinibresistant nonsmall cell lung cancer |
|
https://doi.org/10.18632/oncotarget.2891
|
| 814-824 |
|
| cmyc copy number gain is a powerful prognosticator of disease outcome in cervical dysplasia |
|
https://doi.org/10.18632/oncotarget.2706
|
| 825-835 |
|
| The inverse relationship between bladder and liver in 4aminobiphenylinduced DNA damage |
|
https://doi.org/10.18632/oncotarget.2722
|
| 836-845 |
|
| PKM2 promotes metastasis by recruiting myeloidderived suppressor cells and indicates poor prognosis for hepatocellular carcinoma |
|
https://doi.org/10.18632/oncotarget.2749
|
| 846-861 |
|
| The ubiquitin ligase Siah is a novel regulator of Zeb1 in breast cancer |
|
https://doi.org/10.18632/oncotarget.2696
|
| 862-873 |
|
| TWIST1 and TWIST2 promoter methylation and protein expression in tumor stroma influence the epithelialmesenchymal transitionlike tumor budding phenotype in colorectal cancer |
|
https://doi.org/10.18632/oncotarget.2716
|
| 874-885 |
|
| HDAC2 deregulation in tumorigenesis is causally connected to repression of immune modulation and defense escape |
|
https://doi.org/10.18632/oncotarget.2816
|
| 886-901 |
|
| An HSV2 based oncolytic virus can function as an attractant to guide migration of adoptively transferred T cells to tumor sites |
|
https://doi.org/10.18632/oncotarget.2817
|
| 902-914 |
|
| DNA methylome analysis identifies epigenetic silencing of FHIT as a determining factor for radiosensitivity in oral cancer: an outcomepredicting and treatmentimplicating study |
|
https://doi.org/10.18632/oncotarget.2821
|
| 915-934 |
|
| FGF8 promotes colorectal cancer growth and metastasis by activating YAP1 |
|
https://doi.org/10.18632/oncotarget.2822
|
| 935-952 |
|
| EphrinB1: novel microtubule associated protein whose expression affects taxane sensitivity |
|
https://doi.org/10.18632/oncotarget.2823
|
| 953-968 |
|
| Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer |
|
https://doi.org/10.18632/oncotarget.2824
|
| 969-978 |
|
| Atypical ubiquitin E3 ligase complex Skp1PamFbxo45 controls the core epithelialtomesenchymal transitioninducing transcription factors |
|
https://doi.org/10.18632/oncotarget.2825
|
| 979-994 |
|
| Targeting of TGFβactivated protein kinase 1 inhibits chemokine CC motif receptor 7 expression tumor growth and metastasis in breast cancer |
|
https://doi.org/10.18632/oncotarget.2739
|
| 995-1007 |
|
| Intrinsic TGFβ2triggered SDF1CXCR4 signaling axis is crucial for drug resistance and a slowcycling state in bone marrowdisseminated tumor cells |
|
https://doi.org/10.18632/oncotarget.2826
|
| 1008-1019 |
|
| Silencing of CXCR4 sensitizes triplenegative breast cancer cells to cisplatin |
|
https://doi.org/10.18632/oncotarget.2741
|
| 1020-1030 |
|
| Reciprocal activation between IL6/STAT3 and NOX4/Akt signalings promotes proliferation and survival of nonsmall cell lung cancer cells |
|
https://doi.org/10.18632/oncotarget.2671
|
| 1031-1048 |
|
| ZHX2 enhances the cytotoxicity of chemotherapeutic drugs in liver tumor cells by repressing MDR1 via interfering with NFYA |
|
https://doi.org/10.18632/oncotarget.2832
|
| 1049-1063 |
|
| Knockdown of a novel lincRNA AATBC suppresses proliferation and induces apoptosis in bladder cancer |
|
https://doi.org/10.18632/oncotarget.2833
|
| 1064-1078 |
|
| Targeted Hsp70 expression combined with CIKactivated immune reconstruction synergistically exerts antitumor efficacy in patientderived hepatocellular carcinoma xenograft mouse models |
|
https://doi.org/10.18632/oncotarget.2835
|
| 1079-1089 |
|
| The microRNA218~Survivin axis regulates migration invasion and lymph node metastasis in cervical cancer |
|
https://doi.org/10.18632/oncotarget.2836
|
| 1090-1100 |
|
| MicroRNA130a associates with ribosomal protein L11 to suppress cMyc expression in response to UV irradiation |
|
https://doi.org/10.18632/oncotarget.2728
|
| 1101-1114 |
|
| Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma |
|
https://doi.org/10.18632/oncotarget.2747
|
| 1115-1127 |
|
| Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma |
|
https://doi.org/10.18632/oncotarget.2731
|
| 1128-1142 |
|
| Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosomedependent cancer multidrug resistance |
|
https://doi.org/10.18632/oncotarget.2732
|
| 1143-1156 |
|
| Mitochondrial p32 is upregulated in Myc expressing brain cancers and mediates glutamine addiction |
|
https://doi.org/10.18632/oncotarget.2708
|
| 1157-1170 |
|
| Filamin C a dysregulated protein in cancer revealed by labelfree quantitative proteomic analyses of human gastric cancer cells |
|
https://doi.org/10.18632/oncotarget.2645
|
| 1171-1189 |
|
| Temozolomide resistance in glioblastoma occurs by miRNA9targeted PTCH1 independent of sonic hedgehog level |
|
https://doi.org/10.18632/oncotarget.2778
|
| 1190-1201 |
|
| A switch from CD44+ cell to EMT cell drives the metastasis of prostate cancer |
|
https://doi.org/10.18632/oncotarget.2841
|
| 1202-1216 |
|
| Dichloroacetate a selective mitochondriatargeting drug for oral squamous cell carcinoma: a metabolic perspective of treatment |
|
https://doi.org/10.18632/oncotarget.2721
|
| 1217-1230 |
|
| Aspartate βhydroxylase expression promotes a malignant pancreatic cellular phenotype |
|
https://doi.org/10.18632/oncotarget.2840
|
| 1231-1248 |
|
| Histone demethylase RBP2 decreases miR21 in blast crisis of chronic myeloid leukemia |
|
https://doi.org/10.18632/oncotarget.2859
|
| 1249-1261 |
|
| The Na+/H+ exchanger NHE1 as a novel coadjuvant target in paclitaxel therapy of triplenegative breast cancer cells |
|
https://doi.org/10.18632/oncotarget.2860
|
| 1262-1275 |
|
| miR26a and miR214 downregulate expression of the PTEN gene in chronic lymphocytic leukemia but not PTEN mutation or promoter methylation |
|
https://doi.org/10.18632/oncotarget.2626
|
| 1276-1285 |
|
| A class of genes in the HER2 regulon that is poised for transcription in breast cancer cell lines and expressed in human breast tumors |
|
https://doi.org/10.18632/oncotarget.2676
|
| 1286-1301 |
Clinical Research Papers
|
| Cell type specific gene expression analysis of prostate needle biopsies resolves tumor tissue heterogeneity |
|
https://doi.org/10.18632/oncotarget.2744
|
| 1302-1314 |
|
| PIK3CA mutations in nonsmall cell lung cancer NSCLC: Genetic heterogeneity prognostic impact and incidence of prior malignancies |
|
https://doi.org/10.18632/oncotarget.2834
|
| 1315-1326 |
|
| Molecular profiling of endometrial carcinoma precursor primary and metastatic lesions suggests different targets for treatment in obese compared to nonobese patients |
|
https://doi.org/10.18632/oncotarget.2675
|
| 1327-1339 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLCß
